检索结果-南通市图书馆

Mechanism of T cell regulation by microRNAs

在线全文

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2013年第3期10卷 131-137页

作者： Juan Liu chang-ping wu Bin-Feng Lu Jing-Ting Jiang Department of Tumor Biological Treatment The Third Affiliated Hospital of Soochow University Department of Immunology University of Pittsburgh School of Medicine

MicroRNAs(miRNAs) are small,non-coding single-stranded RNAs that can modulate target gene expression at posttranscriptional level and participate in cell proliferation,differentiation,and apoptosis.T cells have important functions in acquired immune response;miRNAs regulate this immune response by targeting the mRNAs of genes involved in T cell development,proliferation,differentiation,and function.For instance,miR-181 family members function in progression by targeting Bcl2 and CD69,among others.MiR-17 to miR-92 clusters function by binding to CREB1,PTEN,and Bim.Considering that the suppression of T cell-mediated immune responses against tumor cells is involved in cancer progression,we should investigate the mechanism by which miRNA regulates T cells to develop new approaches for cancer treatment.

关键词： microRNA 调节性T细胞调控机制细胞免疫反应 miRNA 癌症治疗转录后水平微RNA

Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2011年第8期17卷 1082-1087页

作者： Xiao-Dong Li Hua Shen ling-Ting Jiang Han-Ze Zhang Xiao Zheng Yong-Qian Shu chang-ping wu Department of Oncology the Third Affiliated Hospital of So-ochow University Changzhou 213003 Jiangsu Province China Department of Oncology the FirstAffiliated Hospital of Nanjing Medical University Nanjing210029 Jiangsu Province China Department of Epidemiology and Biostatistics Nanjing Medical University Nanjing 210029 Jiangsu ProvinceChina

AIM:To compare the efficacy and safety of paclitaxel combined with fluorouracil plus cisplatin(PCF),and oxaliplatin combined with fluorouracil plus leucovorin(FOLFOX-4) regimens for advanced gastric cancer(AGC).METHODS:Ninety-four patients with AGC were randomly assigned to receive paclitaxel(50 mg/m2 iv) on days 1,8 and 15,cisplatin(20 mg/m2 iv) and ? uorouracil(750 mg/m2 iv) on days 1-5,or oxaliplatin(85 mg/m2 iv) and leucovorin(200 mg/m2 iv) on day 1,followed by bolus fluorouracil(400 mg/m2 iv) and fluorouracil(600 mg/m2 iv) on days 1 and 2.The primary end point was the 1-year survival time.RESULTS:The overall response rate(ORR) of the pa-tients was 48.0% and 45.5% to PCF and FOLFOX-4,respectively.The disease control rate(DCR) of PCF and FOLFOX-4 was 82.0% and 81.8%,respectively.The median survival times(MSTs) of the patients were 10.8 and 9.9 mo,respectively,after treatment with PCF and FOLFOX-4.The 1-year survival rate of the patients was 36.0% and 34.1%,respectively,after treatment with PCF and FOLFOX-4.No significant difference was observed in ORR,DCR,MST or 1-year survival rate between the two groups.The most common adverse events were anemia,nausea and vomiting,and grade 3/4 alopecia in PCF treatment group,and anemia,grade 1/2 neurotoxic effect and grade 3/4 neutropenia in FOLFOX-4 treatment group.CONCLUSION:Patients with AGC have a similar response rate to PCF and FOLFOX-4 regimens with a similar survival rate.The PCF and FOLFOX-4 regimens are efficacious and tolerable as a promising therapy for AGC.

关键词：奥沙利铂紫杉醇治疗胃癌晚期基础 VS 醇基

Metabolism of high density lipoproteins in liver cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2007年第23期13卷 3159-3163页

作者： Jing-Ting Jiang Ning Xu chang-ping wu Department of Tumor Biological Treatment the Third Affiliated Hospital of Suzhou University Changzhou 213003 Jiangsu Province China Section of Clinical Chemistry & Pharmacology Lund University S-221 85 Lund Sweden

Liver plays a vital role in the production and catabolism of plasma lipoproteins. It depends on the integrity of cellular function of liver, which ensures homeostasis of lipid and lipoprotein metabolism. When liver ca... 详细信息

关键词：肝癌高密度脂蛋白代谢细胞

Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer:a multicenter,randomized,double-blinded,placebo-controlled,phaseⅡclinical trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2017年第12期36卷 677-685页

作者： Rui-Hua Xu Lin Shen Ke-Ming Wang Gang wu Chun-Mei Shi Ke-Feng Ding Li-Zhu Lin Jin-Wan Wang Jian-ping Xiong chang-ping wu Jin Li Yun-Peng Liu Dong Wang Yi Ba Jue-ping Feng Yu-Xian Bai Jing-Wang Bi Li-Wen Ma Jian Lei Qing Yang Hao Yu Department of Medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhou 510060GuangdongP.R.China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education) Department of Gastrointestinal OncologyPeking University Cancer Hospital&InstituteNo 52Fucheng RoadHaidian DistrictBeijing 100142P.R.China Department of Medical Oncology Second Affiliated Hospital of Nanjing Medical UniversityNanjing 210011JiangsuP.R.China Cancer Center of Union Hospital Tongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030HubeiP.R.China Department of Medical Oncology Fujian Medical University Union HospitalFuzhou 350001FujianP.R.China Department of Surgical Oncology Second Hospital Affiliated to Zhejiang University School of MedicineHangzhou 310009ZhejiangP.R.China Department of Oncology First Affiliated Hospital of Guangzhou Medical University of Chinese MedicineGuangzhou 510405GuangdongP.R.China Department of Medical Oncology Chinese Academy of Medical Sciences Cancer HospitalBeijing 100021P.R.China Department of Medical Oncology First Affiliated Hospital of Nanchang UniversityNanchang 330006JiangxiP.R.China Department of Medical Oncology First People’s Hospital of ChangzhouChangzhou 213003JiangsuP.R.China Department of Medical Oncology Fudan University Cancer HospitalShanghai 200032P.R.China Department of Medical Oncology First Hospital of China Medical UniversityShenyang 110001LiaoningP.R.China Cancer Center Daping Hospital and Institute of Surgery ResearchThird Military Medical UniversityChongqing 400042P.R.China Department of Gastrointestinal Medical Oncology Tianjin Medical University Cancer Institute and HospitalTianjin 300060P.R.China Department of Oncology PuAi Hospital of Tongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430032HubeiP.R.China Department of Medical Oncology Harbin Medical University Cancer Hospit

Background: Metastatic colorectal cancer(mCRC) patients with progressive disease after all available standard therapies need new medication for further treatment. Famitinib is a small-molecule multikinase inhibitor, with promising anticancer activities. This multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial was designed to evaluate the safety and efficacy of famitinib in mCRC.Methods: Famitinib or placebo was administered orally once daily. The primary endpoint was progression-free survival(PFS). Secondary endpoints included objective response rate(ORR), disease control rate(DCR), overall survival(OS), quality-of-life(QoL), and safety.Results: Between July 18,2012 and Jan 22,2014, a total of 167 patients were screened, and 154 patients were randomized in a 2:1 ratio to receive either famitinib(n = 99) or placebo(n = 55). The median PFS was 2.8 and 1.5 months in the famitinib and placebo groups(hazard ratio = 0.60,95% confidence interval = 0.41-0.86, P = 0.004). The DCR was 59.8% and 31.4%(P = 0.002) and the ORR was 2.2% and 0.0%(P = 0.540) in the famitinib and placebo groups,respectively. The most frequent grade 3-4 adverse events were hypertension(11.1%), hand-foot syndrome(10.1%),thrombocytopenia(10.1%) and neutropenia(9.1%). Serious adverse events occurred in 11(11.1%) patients in the famitinib group and 5(9.1%) in the placebo group(P = 0.788). The median OS of the famitinib and placebo groups was 7.4 and 7.2 months(P = 0.657).Conclusion: Famitinib prolonged PFS in refractory mCRC patients with acceptable tolerability.Trial registration This study was registered on ClinicalTrials.gov(NCT01762293) and was orally presented in the 2015 ASCO-Gastrointestinal

关键词： Colorectal cancer Famitinib Efficacy Safety

Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2006年第3期12卷 457-459页

作者： chang-ping wu Jing-Ting Jiang Min Tan Yi-Bei Zhu Mei Ji Kuan-Feng Xu Jie-Min Zhao Guang-Bo Zhang Xue-Guang Zhang The Third Affiliated Hospital of Suzhou University Changzhou213003 Jiangsu Province China Institute of Biotechnology Suzhou University KeyLaboratory of Clinical Immunology of Jiangsu Province Suzhou215007 Jiangsu Province China 不详

AIM:To investigate the expression of co-stimulatorymolecule B7-H3 in gastric carcinoma and adenomatissue as well as normal gastric tissue and to explore therelationship between B7-H3 expression and pathologicalfeatures and prognosis of gastric carcinoma.METHODS:B7-H3 expression was detected in 102samples of human gastric carcinoma and 10 samples ofgastric adenoma and 10 samples of normal gastric tissueby immunohistochemical assay.Correlation betweenthe expression of B7-H3 and the patients'age,sex,gastric carcinoma locus,tumor size,tissue type,tumorinfiltration depth,differentiation degree,lymph nodemetastasis,and survival time was analyzed.RESULTS:B7-H3 was expressed in all gastric adenomasamples and in 58.8% samples of gastric carcinoma.B7-H3 expression in gastric carcinoma samples wasnot related with the patients'age,sex,lymph nodemetastasis,and tumor size(P>0.05),but with thesurvival time,infiltration depth of tumor and tissue type.CONCLUSION:Detection of B7-H3 expression in gastriccarcinoma tissue is beneficial to the judgment of theprognosis of gastric carcinoma patients and the choice oftreatment.

关键词：基因表达胃癌组织学疾病预防

B7-H4 Expression and Increased Death Risk of Cancer Patients： A Meta-Analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Clinical oncology and cancer resexreh 2011年第4期8卷 229-234页

作者： Jing-ting JIANG chang-ping wu Xiao ZHENG Yao ZHAO Bin XU Bin-feng LU Yue-ping SHEN Department of Tumor Biological Treatment Key Laboratory of Biotechnology ofChangzhou the Third Affiliated HospitalSoochow University Changzhou 213003Jiangsu Province China Department of Epidemiology andBiostatistics Radiation Medicine and PublicHealth School of Soochow University Suzhou215123 Jiangsu Province China Department of Immunology University otPittsburgh School of Medicine Pittsburgh PA15261 USA

The relationship between higher levels of B7-H4 expression and death risk of cancer patients remains to be clarified. In the current study, information from an ordinary scale and those from several outcome scales were combined to make a single estimate. PubMed databases were searched for survival studies on the hazard ratios (HR) of malignant tumors associated with higher B7-H4 expression from 1999 to 2010. The fixed effect model was used to estimate the combined HRs of six studies. Sensitivity analysis was performed to assess the stability. Publication bias was also estimated. Six studies that meet the inclusion criteria were identified; these studies reported the associations between the higher B7-H4 expression and death risk of cancer patients. A 42% increase in death risk was observed in patients with higher B7-H4 expression (HR = 1.42; 95% confidence interval: 1.16–1.72). Sensitivity analyses found the results robust. The analysis shows that higher levels of B7-H4 expression are associated with the death risk of patients suffering from various cancers. B7-H4 may be a negative regulatory molecule for antitumor immune responses and a molecular target for tumor immunotherapy.

关键词：癌症患者 Meta分析风险死亡 PubMed 固定效应模型恶性肿瘤数据库检索

Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China： A Prospective, Multicenter, Noninterventional Study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2018年第15期131卷 1767-1775页

作者： Jian-Qiu wu Yong-ping Song Li-ping Su Ming-Zhi Zhang Wei Li Yu Hu Xiao-Hong Zhang Yu-Huan Gao Zuo-Xing Niu Ru Feng Wei Wang Jie-Wen Peng Xiao-Lin Li Xue-Nong Ouyang chang-ping wu Wei-Jing Zhang Yun Zeng Zhen Xiao Ying-Min Liang Yong-Zhi Zhuang Ji-Shi Wang Zi-Min Sun Hai Bai Tong-Jian Cui Ji-Feng Feng Department of Oncology Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital Nanjing Jiangsu 210008 China Department of Hematology Henan Cancer Hospital Zhengzhou Henan 450000 China Department of Hematology Shanxi Cancer Hospital Taiyuan Shanxi 030013 China Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450000 China Department of Oncology Jilin University First Affiliated Hospital Changchun Jilin 130000 China Department of Hematology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430072 China Department of Hematology The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang 310009 China Department of Hematology Fourth Hospital of Hebei Medical University Shijiazhuang Hebei 050000 China Department of Oncology Affiliated Hospital of Shandong Academy of Medical Sciences Jinan Shandong 250000 China Department of Hematology Medical University Nanfang Hospital Guangzhou Guangdong 510000 China Department of Oncology Guangdong Foshan First Hospital Foshan Guangdong 528000 China Department of Oncology Guangdong Zhongshan People's Hospital Zhongshan Guangdong 528403 China Department of Hematology Xiangya Hospital Central South University Changsha Hunan 410008 China Department of Oncology Fuzhou General Hospital of Nanjing Military Command Fuzhou Fujian 350001 China Department of Oncology Changzhou First People's Hospital Changzhou Jiangsu 213000 China Department of Oncology 307 Hospital of Chinese People's Liberation Army Beijing 100070 China TDepartment of Hematology First Affiliated Hospital of Kunming Medical University Kunming Yunnan 650221 China Department of Hematology Affiliated Hospital of Neimenggu Medical College Hohhot Huhehaote Inner Mongolia 010050 China Department of Hematology The Fourth Military Medical University Affiliated Tangdu Hospital X

Background： Prospective real-life data on the safety and effectiveness of rituximab in Chinese patients with diffuse large B-cell lymphoma （DLBCL） or follicular lymphoma （FL） are limited. This real-world study aimed to evaluate long-term safety and effectiveness outcomes ofrituximab plus chemotherapy （R-chemo） as first-line treatment in Chinese patients with DLBCL or FL. Hepatitis B virus （HBV） reactivation management was also investigated. Methods： A prospective, multicenter, single-arm, noninterventional study of previously untreated CD20-positive DLBCL or FL patients receiving first-line R-chemo treatment at 24 centers in China was conducted between January 17, 2011 and October 31, 2016. Enrolled patients underwent safety and effectiveness assessments after the last rituximab dose and were followed up for 3 years. Effectiveness endpoints included progression-free survival （PFS） and overall survival （OS）. Safety endpoints were adverse events （AEs）, serious AEs, drug-related AEs, and AEs of special interest. We also reported data on the incidence of HBV reactivation. Results： In total, 283 previously untreated CD20-positive DLBCL and 31 FL patients from 24 centers were enrolled. Three-year PFS was 59% （95% confidence interval [CI]： 50-67%） for DLBCL patients and 46% （95% CI： 20-69%） for FL patients. For DLBCL patients, multivariate analyses showed that PFS was not associated with international prognostic index, tumor maximum diameter, HBV infection status, or number ofrituximab treatment cycles, and OS was only associated with age 〉60 years （P 〈 0.05）. R-chemo was well tolerated. The incidence of HBV reactivation in hepatitis B surface antigen （HBsAg）-positive and HBsAg-negative/hepatitis B core antibody-positive patients was 13% （3/24） and 4% （3/69）, respectively. Conclusions： R-chemo is effective and safe in real-world clinical practice as first-line treatment for DLBCL and FL in China, and that HBV reactivation during R-chemo is manageable with preventive measures and treatment.

关键词： Asian Hematopoietic Malignancy Hepatitis B Virus Observational Study Rituximab

High expression of CD11c indicates favorable prognosis in patients with gastric cancer

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第31期21卷 9403-9412页

作者： Yuan Wang Bin Xu Wen-Wei Hu Lu-Jun Chen chang-ping wu Bin-Feng Lu Yue-ping Shen Jing-Ting Jiang Department of Tumor Biological Treatment the Third Affiliated Hospital of Soochow University School of Clinical Medicine North China University of Science and Technology Department of Immunology University of Pittsburgh Jiangsu Key Laboratory of Preventive and Trans-lational Medicine for Geriatric Diseases School of Public HealthSoochow University

AIM: To determine the relationship between CD11 c expression level and prognosis in patients with gastric cancer(GC).METHODS: This retrospective survival study was performed from July 31,2008 to June 30,2014. Our study inclusion criteria included all the patients with GC who underwent surgical resection between January 1998 and December 2009 in the Third Affiliated Hospital of Soochow University. CD11 c expression levels in 140 patients with GC at different UICC stages were evaluated using immunohistochemistry,and GC tissues from 16 cases were further verified by q RTPCR. The χ2 test was used to compare the patientand disease-related factors between the low CD11 c expression group and the high expression group. Univariate probabilities of overall survival(OS) and disease-free survival(DFS) were assessed using the Kaplan-Meier method. The log rank test was used to compare survival curves. Different multivariate COX models were used to estimate the association between CD11 c expression and both death and recurrence riskin GC patients.RESULTS: The average CD11 c expression level was 5.1 ± 1.8/high power field(HPF) in 10 gastritis samples,4.5 ± 2.3/HPF in 10 gastric polyp samples and 9.7 ± 6.3/HPF in 140 gastric cancer samples,respectively. The CD11 c expression level was significantly decreased from UICC stage Ⅰ to stage Ⅳ(stage Ⅰ: 16.0 ± 7.4,stage Ⅱ: 10.4 ± 5.5,stage Ⅲ: 9.4 ± 6.1,stage Ⅳ: 5.3 ± 3.2,P < 0.001). Patients in the high CD11 c expression group had a greater 3- and 5-year OS probability and longer median survival time compared with the low CD11 c expression group,(67.7% vs 39.2%; 51.4% vs 29.0%; 67.0 mo vs 28.0 mo; χ2 = 6.80,P = 0.009),and had a greater 3- and 5-year DFS probability and longer median DFS time(63.7% vs 24.0%; 49.1% vs 11.9%; 64.0 mo vs 18.0 mo; χ2 = 15.39,P < 0.001). Patients with high CD11 c high expression had a reduced risk of death(HR = 0.56,95%CI: 0.33-0.98,P < 0.05) and relapse(HR = 0.39,95%CI: 0.23-0.67,P < 0.01) compared with patients with low CD11 c expression after adjustment of

关键词： CD11c Gastric cancer Dendritic cell Tumor microenv

A new genetic factor for root gravitropism in rice (Oryza sativa L.)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Zhejiang University-Science B(Biomedicine & Biotechnology) 2009年第10期10卷 777-783页

作者： Jiang-hua SHI Xi HAO Zhong-chang wu ping wu State Key Laboratory of Plant Physiology and Biochemistry College of Life Sciences Zhefiang University Hangzhou 310058 China

Root gravitropism is one of the important factors to determine root architecture. To understand the mechanism underlying root gravitropism, we isolated a rice (Xiushui63) mutant defective in root gravitropism, designated as gls1. Vertical sections of root caps revealed that gls1 mutant displayed normal distribution of amyloplast in the columella cells compared with the wild type. The gls1 mutant was less sensitive to 2,4-dichlorophenoxyacetic acid (2,4-D) and α-naphthaleneacetic acid (NAA) than the wild type. Genetic analysis indicated that the phenotype of gls1 mutant was caused by a single recessive mutation, which is mapped in a 255-kb region between RM16253 and CAPS1 on the short arm of chromosome 4.

关键词：水稻根系遗传因素二氯苯氧乙酸 4号染色体突变体向地性遗传分析基因突变